99981-79-0Relevant academic research and scientific papers
Discovery of a PCAF Bromodomain Chemical Probe
Moustakim, Moses,Clark, Peter G. K.,Trulli, Laura,Fuentes de Arriba, Angel L.,Ehebauer, Matthias T.,Chaikuad, Apirat,Murphy, Emma J.,Mendez-Johnson, Jacqui,Daniels, Danette,Hou, Chun-Feng D.,Lin, Yu-Hui,Walker, John R.,Hui, Raymond,Yang, Hongbing,Dorrell, Lucy,Rogers, Catherine M.,Monteiro, Octovia P.,Fedorov, Oleg,Huber, Kilian V. M.,Knapp, Stefan,Heer, Jag,Dixon, Darren J.,Brennan, Paul E.
, p. 827 - 831 (2017/01/14)
The p300/CBP-associated factor (PCAF) and related GCN5 bromodomain-containing lysine acetyl transferases are members of subfamily I of the bromodomain phylogenetic tree. Iterative cycles of rational inhibitor design and biophysical characterization led to the discovery of the triazolopthalazine-based L-45 (dubbed L-Moses) as the first potent, selective, and cell-active PCAF bromodomain (Brd) inhibitor. Synthesis from readily available (1R,2S)-(?)-norephedrine furnished L-45 in enantiopure form. L-45 was shown to disrupt PCAF-Brd histone H3.3 interaction in cells using a nanoBRET assay, and a co-crystal structure of L-45 with the homologous Brd PfGCN5 from Plasmodium falciparum rationalizes the high selectivity for PCAF and GCN5 bromodomains. Compound L-45 shows no observable cytotoxicity in peripheral blood mononuclear cells (PBMC), good cell-permeability, and metabolic stability in human and mouse liver microsomes, supporting its potential for in vivo use.
